Objective: To investigate the actual dual antiplatelet therapy (DAPT) duration after drug-eluting stent (DES) treatment in China.
advent of new generation DESs, which are associated with a consistent reduction in stent thrombosis (ST) compared with first-generation DESs [3] , the optimal duration of DAPT is under debate. Although a reduced DAPT duration was considered safe and with a reduced risk of bleeding complications [4] [5] [6] [7] , ST after more than 12 months after DES implantation was observed [8] . Thus, updated guidelines with adjusted DAPT duration after DES implantation has been recommended, according to the patients' bleeding and ischemic risks [9] [10] [11] .
For real clinical cases, DAPT duration after DES implantation is more complicated, determined by both physicians' comprehension of the complex guidelines and the patients' compliance [12] . Data from the PARIS (patterns of nonadherence to antiplatelet regimens in stented patients) registry suggested that the proportions of patients with DAPT coverage after the DES implantation at 1-year and 2-year follow-up were 76.7 and 42.7%, respectively, in 15 clinical sites in US and Europe [13] . However, less has been reported about the situation in China. In this study, we analyzed a large number of cases in the largest cardiovascular center in China to investigate DAPT duration and identify associated factors after DES implantation.
| P A TI E NT S A ND M E TH ODS

| Study population
This was a prospective observational study, which consecutively enrolled 10,724 patients undergoing PCI treatment at Fu Wai Hospital, National Center for Cardiovascular Diseases (Beijing, China) from January to December 2013. After excluding patients implanted with a bare metal stent alone (n 5 64), treated with balloon angioplasty alone (n 5 237), failed PCI (n 5 237), died during follow-up (n 5 113), and unfinished 2-year follow-up (n 5 154), a total of 9,919 patients with the DES implantation were analyzed in this study (Figure 1 ). The study protocol was approved by the Institutional Review Board, and written informed consent was provided by patients before the intervention.
| Procedure and medications
The PCI strategy and stent type were left to the treating physician's discretion. Before the procedure, if the patient was not taking longterm aspirin and clopidogrel, selective PCI patients received oral 300 mg aspirin and clopidogrel (loading dose, 300 mg). Acute coronary syndrome (ACS) patients scheduled for PCI were given the same dose of aspirin and clopidogrel (loading-dose 300 or 600 mg) as soon as possible. During the procedure, unfractionated heparin (100 U/kg) was administered to all patients, with glycoprotein IIb/IIIa inhibitors based on the operator's judgment. In 2013, other P2Y12 inhibitors, such as prasugrel and ticagrelor, were not routinely used in our center; therefore, only 16 patients (0.16%) received ticagrelor (loading dose 180 mg) during that time. 
| Patient follow-up
| Definitions
The duration of DAPT was defined as the length between the date of the index PCI procedure and DAPT cessation. The patients were divided into three groups according to DAPT duration: <1 year (0-11 months), 51 year (11-13 months), and >1 year (>13 months). New generation DESs was defined as the second generation and biodegradable polymer DESs. Myocardial infarction (MI) was defined according to the third universal definition of MI [14] . Target vessel revascularization (TVR) was defined as the repeated revascularization by PCI or surgery of the target vessel. Bleeding was defined by the Bleeding Academic Research Consortium (BARC) [15] . All endpoints were adjudicated centrally by two independent cardiologists and disagreements were resolved by consensus.
| Statistical analysis
Continuous variables were presented as the mean 6 standard deviation, and Student's t tests or the Mann-Whitney rank sum test were performed for cross-group comparisons. Categorical variables were presented as frequency or ratio. The normally distributed continuous variables were compared using the one-way ANOVA test, and categori- 
| Comparison among patients with different DAPT durations
The proportions of patients (9,919 in total) with DAPT durations of <1 year 5 1 year, and >1 year were 2.6, 27.2, and 70.2%, respectively.
Patients' basic characteristics and clinical outcomes during the followup are shown in Table 1 . Basic characteristics were nearly the same across three groups, except for slightly older age, lower rate of hyperlipidemia and a higher rate of previous stroke in the group with DAPT duration <1 year. More stents/patient was found for the group of DAPT duration >1 year. During follow-up, patients in the >1 year group experienced more revascularization, and patients in the <1 year group had more stroke and bleeding events. DAPT in patients pre- 
| Factors associated with different DAPT durations
The multivariable analysis results for all patients indicated that independent associated factors for shortening DAPT duration (<1 year vs.
1 year) were age and bleeding condition (BARC 2) during the follow-up, whereas patients with hyperlipidemia, previous stroke and those who experienced TVR during follow-up were prone to prolonged DAPT duration (Figure 4) . When only patients with DAPT duration 1 year were considered, the independent predictors of prolonging DAPT duration (>1 year vs. 51 year) included TVR during follow-up (OR 2.50, 95% CI 2.04-3.06, P < 0.001), stent number/patient (OR 1.10, 95% CI 1.05-1.15, P < 0.001) and previous coronary artery bypass grafting (CABG) (OR 0.76, 95% CI 0.61-0.96, P 5 0.02). Other clinical factors, such as increased risk of bleeding (e.g., age >75 years, prior stroke, low body weight <60 kg, renal dysfunction) and high ischemic risk (e.g., AMI, diabetes mellitus, peripheral artery disease, prior cardiovascular event, left main stenting, bifurcation stenting) were not associated with DAPT duration ( Figure 5 ).
| D ISC USSION
In this study, DAPT duration after DES implantation was investigated in a large number of patients in a large Chinese cardiovascular center.
The major findings of this study were as follows: (1) In 2012, Chinese guidelines recommended at least 1-year of DAPT after DES implantation [2] , and it was not until 2016 that the renewed guideline recommended that individualized DAPT duration should be determined based on the balance between bleeding and ischemic risks for each particular patient [11] . The patients in this study were followed up in 2013-2015. Thus, at least 1-year of DAPT was an appropriate treatment duration at that time. This finding indicated the effectiveness of clinical guidelines in increasing adherence to DAPT in China.
The clinical presentation of AMI is predicted as an important factor for DAPT duration. A duration of 1-year DAPT after AMI was recommended by previous guidelines [1, 2] based on the duration of treatment in pivotal P2Y12 receptor inhibitor studies [16] [17] [18] . However, DAPT duration longer than 1 year after AMI [19] [20] [21] [22] [23] [24] is recommended for patients who were not at high risk for bleeding. In addition, the second generation of DES is another important factor that clinicians should consider for adjusting DAPT duration. Recently, numerous studies demonstrated that patients with 3-6 months of DAPT compared with 12 months after implantation of the second-generation DES had lower rates of bleeding, with similar rates of mortality, MI, and ST [4] [5] [6] [7] . Therefore, current guidelines recommend DAPT for 6 months after the 
| Study limitations
Several limitations must be considered. First, the data from this study was obtained from the same clinical center, not representing all of China. Second, the specified modes of DAPT cessation, including discontinuation, interruption, and disruption (with prognostic impacts 
| C ONC LUSI ON
The 1-year DAPT after DES was 97.4% in this large Chinese cohort of real-world patients. However, DAPT duration was not adjusted due to different clinical scenarios. These findings demonstrated good adherence to DAPT after DES in China, but gaps remain in evidence-based practice.
